gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Somatostatin receptor 1

somatostatin receptor, SSTR1
Somatostatin acts at many sites to inhibit the release of many hormones and other secretory proteins. The biological effects of somatostatin are probably mediated by a family of G protein-coupled receptors that are expressed in a tissue-specific manner. The encoded protein is a member of the superfamily of somatostatin receptors having seven transmembrane segments, and is expressed in highest levels in jejunum and stomach. [provided by RefSeq, Jul 2008] (from NCBI)
Sponsored links
Top mentioned proteins: somatostatin, CAN, SSTR2, HAD, SSTR5
Papers on somatostatin receptor
New therapeutic agents for acromegaly.
Melmed, Los Angeles, United States. In Nat Rev Endocrinol, Feb 2016
The currently available somatostatin receptor ligands (SRLs) and growth hormone (GH) antagonists are used to control levels of GH and insulin-like growth factor 1 (IGF-1) in patients with acromegaly.
Synthesis, Characterization, and In Vitro Evaluation of New (99m)Tc/Re(V)-Cyclized Octreotide Analogues: An Experimental and Computational Approach.
Jurisson et al., Columbia, United States. In Inorg Chem, Feb 2016
UNASSIGNED: Radiolabeled proteolytic degradation-resistant somatostatin analogues have been of long-standing interest as cancer imaging and radiotherapy agents for targeting somatostatin receptor-positive tumors.
BMP-6 modulates somatostatin effects on luteinizing hormone production by gonadrotrope cells.
Makino et al., Okayama, Japan. In Peptides, Feb 2016
BMP-6 increased the expression levels of somatostatin receptor (SSTR)5, suggesting that BMP-6 upregulates SSTR activity that leads to reduction of GnRH-induced LH secretion.
Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
Del Vecchio et al., Napoli, Italy. In Ann Nucl Med, Feb 2016
CONCLUSIONS: In MMTC patients, (18)F-FDG-PET/CT provides a useful contribution mainly in evaluating lymph node involvement whereas (111)In-Octreotide SPECT can contribute to the detection and somatostatin receptor characterization especially of bone lesions.
Cardiac neuroendocrine tumour metastases: case reports and review of the literature.
Stokkel et al., Amsterdam, Netherlands. In Nucl Med Commun, Jan 2016
Also, a review of literature is presented on case reports of cardiac NET metastasis in patients detected by somatostatin receptor imaging, including In-pentereotide single photon emission computed tomography/CT, Ga-DOTATATE PET/CT, Ga-DOTANOC PET/CT or Ga-DOTATOC PET/CT.
Ciliated neurons lining the central canal sense both fluid movement and pH through ASIC3.
Grillner et al., Stockholm, Sweden. In Nat Commun, Dec 2015
The somatostatin receptor antagonist counteracts the effects of both a decrease in pH and of somatostatin.
Emerging clinical applications of PET based molecular imaging in oncology: the promising future potential for evolving personalized cancer care.
Basu et al., India. In Indian J Radiol Imaging, Oct 2015
In this review, we bring forth the current trends in molecular imaging with established techniques (PET/CT), with particular emphasis on newer molecules (such as amino acid metabolism and hypoxia imaging, somatostatin receptor based imaging, and hormone receptor imaging) and further potential for FDG.
Current therapies and mortality in acromegaly.
Poiană et al., Bucureşti, Romania. In J Med Life, Oct 2015
A meta-analysis proved that mortality is much lower in operated patients, even uncured, than the entire group of patients and is similar with the general population in patients with GH<1 μg/ L. For the patients with hypersecreting postoperative remnant tumor, those with low chance of surgical cure or with life-threatening comorbidities, medical therapies are available: somatostatin receptor analogues (SRA), dopamine agonists (DA) and GH receptor antagonists.
Pathology: Classification and Immunoprofile.
Perren et al., Bern, Switzerland. In Front Horm Res, 2014
There is no predictive biomarker in use, with the exception of somatostatin receptor (SSTR) 2 expression for predicting the amenability of a tumor to in vivo SSTR targeting for imaging or therapy.
Radiological Imaging: Computed Tomography, Magnetic Resonance Imaging and Ultrasonography.
Rockall et al., Uppsala, Sweden. In Front Horm Res, 2014
Conventional radiological imaging of morphology (anatomy) is usually performed by computed tomography (CT), magnetic resonance imaging (MRI) and ultrasound, whereas functional imaging of somatostatin receptor expression generally utilizes scintigraphy, but recently also positron emission tomography (PET).
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
CLARINET Investigators et al., India. In N Engl J Med, 2014
METHODS: We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced, well-differentiated or moderately differentiated, nonfunctioning, somatostatin receptor-positive neuroendocrine tumors of grade 1 or 2 (a tumor proliferation index [on staining for the Ki-67 antigen] of <10%) and documented disease-progression status.
Neurotransmitter switching in the adult brain regulates behavior.
Spitzer et al., San Diego, United States. In Science, 2013
Changes in postsynaptic dopamine receptor expression matched changes in presynaptic dopamine, whereas somatostatin receptor expression remained constant.
Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling.
Kumar et al., Vancouver, Canada. In Biochim Biophys Acta, 2011
Data demonstrate that cells transfected with SSTR1 or SSTR1/5 negatively regulates EGF mediated effects attributed to the inhibition of EGFR phosphorylation.
Resistance to somatostatin analogs in acromegaly.
Pivonello et al., Napoli, Italy. In Endocr Rev, 2011
Predictors of response are patients' gender, age, initial GH and IGF-I levels, and tumor mass, as well as adequate expression of somatostatin receptor types 2 and 5, those with the highest affinity for octreotide and lanreotide.
Recent progress in the understanding, diagnosis, and treatment of gastroenteropancreatic neuroendocrine tumors.
Kvols et al., Milwaukee, United States. In Ca Cancer J Clin, 2011
Diagnosis of these tumors has been aided by advances in pathological diagnosis and classification and tumor imaging with endoscopic ultrasound and somatostatin receptor fusion imaging.
Overexpression and functional relevance of somatostatin receptor-1, -2, and -5 in endometrium and endometriotic lesions.
Bocci et al., Genova, Italy. In J Clin Endocrinol Metab, 2010
Overexpressed in endomterium inendometriosis.
Profiling of somatostatin receptor subtype expression by quantitative PCR and correlation with clinicopathological features in pancreatic endocrine tumors.
Yagihashi et al., Hirosaki, Japan. In Pancreas, 2010
Data show that the mRNA levels of SSTR1, SSTR2, SSTR3, and SSTR5 were high in PET compared with AC, whereas the expression of SSTR4 was low in PET and AC.
Somatostatin receptor subtypes in human type 2 diabetic islets.
Stridsberg et al., Lisbon, Portugal. In Pancreas, 2010
Studies show that this study may be the basis for further functional studies to evaluate the role of somatostatin receptors sst1 to sst5 in the diabetic state.
The conserved Bardet-Biedl syndrome proteins assemble a coat that traffics membrane proteins to cilia.
Nachury et al., Stanford, United States. In Cell, 2010
Finally, the ciliary targeting signal of somatostatin receptor 3 needs to be directly recognized by the BBSome in order to mediate targeting of membrane proteins to cilia.
SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
Winczyk et al., Łódź, Poland. In Folia Histochem Cytobiol, 2010
The summarized expression pattern of SSTR in the investigated neuroendocrine tumors in our material was: SSTR 1> SSTR 5> SSTR 3> SSTR 2A> SSTR 2B.
share on facebooktweetadd +1mail to friends